NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Dianthus Therapeutics, Inc. (DNTH) Stock Analysis

Dianthus Therapeutics, Inc. (DNTH) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

DNTH

$78.10

−$0.65 (−0.83%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DNTH with… →

DNTH Key Statistics

As of Oct 21, 2026
Trading
Open
$78.89
Previous Close
$78.75
Day's Range
77.26–80.74
52-Week Range
32.22–117.88
Volume
1.19M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.18
Valuation
Market Cap
$4.37B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2,294.37
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.24
Financials (FY)
Revenue (FY)
$2.04M−67.35%
Net Income (FY)
−$162.34M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
55.93M
1-Year Return
+122.95%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
825.45K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, DNTH closed at $78.10, +122.95% over 1 year.

Dianthus Therapeutics, Inc. (DNTH) has a market capitalization of $4.37B.

In fiscal 2025, DNTH reported revenue of $2.04M.

DNTH Stock Return by Calendar Year

Dianthus Therapeutics, Inc. (DNTH) return since Jun 2018: what $10,000 became

1 year
$10,000 $22,295
+122.95%
5 years
$10,000 $7,580
−24.20%
Since Jun 2018
$10,000 $3,362
−66.38%

If you had invested $10,000 in Dianthus Therapeutics, Inc. (DNTH) at the close on June 21, 2018, the earliest close on record here, it would have been worth $3,362 at the close on October 21, 2026: −66.38% in total, −12.26% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+89.52%
2025+89.04%
2024+109.62%
2023+62.50%
2022−90.97%
2021−43.49%
2020−48.28%
2019+165.96%
2018 (partial year)−60.74%

As of October 21, 2026.

DNTH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.04M−$162.34M−7,973.3%
2024$6.24M−$84.97M−1,362.8%
2023$2.83M−$43.56M−1,541.2%
2022$6.42M−$28.48M−443.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.04M—−$177.93M−$162.34M−7,973.3%
2024$6.24M—−$101.86M−$84.97M−1,362.8%
2023$2.83M—−$48.17M−$43.56M−1,541.2%
2022$6.42M—−$29.71M−$28.48M−443.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Dianthus Therapeutics, Inc. (DNTH) is capitalised at $4.37B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 92 employees.

The 52-week range on file runs from $32.22 to $117.88. DNTH last closed at $78.10 on October 21, 2026. That is −$0.65 (−0.83%) against the previous close. The latest close sits 142.4% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $2.04M. Against the prior fiscal year total of $6.24M, that is a change of −67.35%. The same year closed with a net loss of $162.34M. Earnings per share on a trailing basis come to −4.24.

Across the 4 fiscal years on file, revenue moves from $6.42M in 2022 to $2.04M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 2,294.37. On price-to-sales that is 172.5 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is +122.95%. Across 5 years the annualized return works out at −5.39%. The reported beta is 0.18. Annualized volatility over the trailing 8 years is 86.65%.

Growth & Income

The record shows no dividend for DNTH.

Across the complete calendar years on file, 2019 returned +165.96% and 2022 returned −90.97%. Of the 7 complete calendar years on file, 4 finished higher. So far in 2026 the total return is +89.52%.

Peer Comparison

Dianthus Therapeutics, Inc. (DNTH) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Dianthus Therapeutics, Inc. DNTH $4.37B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Dianthus Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Visit website →